Subject
Pharmacology,Immunology,Immunology and Allergy
Reference47 articles.
1. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015
2. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057);Horn;J. Clin Oncol. Official J. Am. Soc. Clin. Oncol.,2017
3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet (London, England),2017
4. Human tumor cells killed by anthracyclines induce a tumor-specific immune response;Fucikova;Cancer Res.,2011
5. Current therapy and development of therapeutic agents for lung cancer;Wang;Cell Insight,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献